Feeds

HIV vaccine safe for Phase II human trials

Canadian university claim no adverse effects from first tests

Intelligent flash storage arrays

Researchers from the Schulich School of Medicine & Dentistry at Canada's University of Western Ontario have issued a statement saying the first phase of clinical trials of an HIV vaccine have produced “no adverse effects observed including local reactions, signs/symptoms and laboratory toxicities”.

The Reg understands the trial of the vaccine, dubbed'SAV001-H' involved only 40 patients, all of which were HIV-positive. Some of those participating in the trial received a placebo.

The researchers say data from the trial is still being analysed, but say the results they have been able to gather show “significant increase in the HIV-1 antibody formations after SAV001-H administration compared to the base line in some patients.”

That result, along with the lack of adverse effects, sees the researchers declare “we are now prepared to take the next steps towards Phase II and Phase III clinical trials” among a wider population.

The vaccine is described as a a “killed whole virus”, a type of vaccine that uses a genetically-engineered version of the HIV virus that is subjected to chemicals and radiation in ways that allow it to fight HIV without hurting the patient. Such vaccines are already used to treat polio, rabies, influenza and other diseases.

There's still a long way to go before SAV001-H becomes widely available. As the USA's national Institutes of Health explains, Phase II trials use a larger sample to test whether a drug “is effective and to further evaluate its safety” while Phase III trials work with more people again to test “effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.” ®

Providing a secure and efficient Helpdesk

More from The Register

next story
SECRET U.S. 'SPACE WARPLANE' set to return from SPY MISSION
Robot minishuttle X-37B returns after almost 2 years in orbit
No sail: NASA spikes Sunjammer
'Solar sail' demonstrator project binned
LOHAN crash lands on CNN
Overflies Die Welt en route to lively US news vid
You can crunch it all you like, but the answer is NOT always in the data
Hear that, 'data journalists'? Our analytics prof holds forth
Experts brand LOHAN's squeaky-clean box
Phytosanitary treatment renders Vulture 2 crate fit for export
Carry On Cosmonaut: Willful Child is a poor taste Star Trek parody
Cringeworthy, crude and crass jokes abound in Steven Erikson’s sci-fi debut
Origins of SEXUAL INTERCOURSE fished out of SCOTTISH LAKE
Fossil find proves it first happened 385 million years ago
America's super-secret X-37B plane returns to Earth after nearly TWO YEARS aloft
674 days in space for US Air Force's mystery orbital vehicle
prev story

Whitepapers

Forging a new future with identity relationship management
Learn about ForgeRock's next generation IRM platform and how it is designed to empower CEOS's and enterprises to engage with consumers.
Cloud and hybrid-cloud data protection for VMware
Learn how quick and easy it is to configure backups and perform restores for VMware environments.
Three 1TB solid state scorchers up for grabs
Big SSDs can be expensive but think big and think free because you could be the lucky winner of one of three 1TB Samsung SSD 840 EVO drives that we’re giving away worth over £300 apiece.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.
Security for virtualized datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.